Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-23-003903
Filing Date
2023-02-08
Accepted
2023-02-08 06:18:08
Documents
45
Period of Report
2022-12-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 531912
2 ex31-1.htm EX-31.1 18317
3 ex31-2.htm EX-31.2 18129
4 ex32-1.htm EX-32.1 6499
5 ex32-2.htm EX-32.2 6639
  Complete submission text file 0001493152-23-003903.txt   2976472

Data Files

Seq Description Document Type Size
6 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT nxen-20221231.xsd EX-101.SCH 24825
7 INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT nxen-20221231_cal.xml EX-101.CAL 27874
8 INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT nxen-20221231_def.xml EX-101.DEF 95865
9 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT nxen-20221231_lab.xml EX-101.LAB 224943
10 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT nxen-20221231_pre.xml EX-101.PRE 170474
39 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 366066
Mailing Address 4340 E KENTUCKY AVE SUITE 206 GLENDALE CO 80246
Business Address 4340 E KENTUCKY AVE SUITE 206 GLENDALE CO 80246 3034957583
NEXIEN BIOPHARMA, INC. (Filer) CIK: 0001625288 (see all company filings)

EIN.: 262049376 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 000-55320 | Film No.: 23596997
SIC: 2834 Pharmaceutical Preparations